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Cancer cells develop under immune surveillance, thus necessitating
immune escape for successful growth. Loss of MHC class I expression
provides a key immune evasion strategy in many cancers, although
the molecular mechanisms remain elusive. MHC class I transactivator
(CITA), known as “NLRC5” [NOD-like receptor (NLR) family, caspase
recruitment (CARD) domain containing 5], has recently been identified
as a critical transcriptional coactivator of MHC class I gene expression.
Herewe show that theMHC class I transactivation pathwaymediated
by CITA/NLRC5 constitutes a target for cancer immune evasion. In all
the 21 tumor types we examined, NLRC5 expression was highly cor-
related with the expression of MHC class I, with cytotoxic T-cell
markers, and with genes in the MHC class I antigen-presentation
pathway, including LMP2/LMP7, TAP1, and β2-microglobulin. Epige-
netic and genetic alterations in cancers, including promoter methyl-
ation, copy number loss, and somatic mutations, were most prevalent
in NLRC5 among all MHC class I-related genes and were associated
with the impaired expression of components of the MHC class I path-
way. Strikingly, NLRC5 expression was significantly associated with
the activation of CD8+ cytotoxic T cells and patient survival inmultiple
cancer types. Thus, NLRC5 constitutes a novel prognostic biomarker
and potential therapeutic target of cancers.
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During cancer progression, neoplastic cells accumulate nu-merous mutations that constitute potentially immunogenic
neo-epitopes. Thus, most tumors concurrently need to use
mechanisms that enable escape from immune surveillance for
successful growth and progression (1). It has been demonstrated
that cancer cells use multiple strategies of immune evasion, in-
cluding increased resistance to cytotoxic T-cell killing, induction of
anergy in activated T cells, elimination of effector T cells, recruit-
ment of regulatory immune cell subsets, and reduced recognition of
tumor-associated antigens by effector T cells (2). Impaired MHC
class I-mediated antigen presentation is a major immune evasion
mechanism in cancer (3, 4), with MHC class I loss reported in
cervical cancer (92%) (5), penile cancer (80%) (6), breast cancer
(71%) (7), nonsmall cell lung cancer (64%) (8), and esophageal
squamous cell carcinoma (67%) (9), among others. Although a
number of mechanisms have been described for HLA loss, includ-
ing the loss of heterozygosity, HLA gene methylation, nonsense/
missense mutations, and loss of TAP1/2 or β2-microglobulin (B2M),
the dominant underlying molecular mechanism seems to reside at
the transcriptional level (10). Transcriptional regulation of MHC
class I genes remained largely undefined until the recent discovery
of CITA (MHC class I transactivator), known as NLRC5 [NOD-
like receptor (NLR) family, caspase recruitment (CARD) domain
containing 5] (11, 12). NLRC5 is an IFN-γ–inducible nuclear pro-
tein (13–15) that specifically associates with and activates promoters
of MHC class I genes by generating a CITA enhanceosome com-
plex with other transcription factors (14, 16, 17). A striking feature
of CITA/NLRC5 is that it does not solely induce MHC class I genes
but also activates other critical genes involved in the MHC class I
antigen-presentation pathway, including the immunoproteasome
component LMP2 (PSMB9), peptide transporter TAP1, and B2M
(14, 17), thus regulating most of the key components in the MHC
class I antigen-presentation machinery. Nlrc5-deficient mice ex-
hibit impaired constitutive and inducible expression of MHC
class I genes in vivo (18–22). In addition, Nlrc5-deficient cells
display an impaired ability to elicit CD8+ T-cell activation, as
evidenced by impaired IFN-γ production and diminished cyto-
lytic activity (18, 19, 21).
Results
Expression of NLRC5 and MHC Class I Genes Is Correlated in Human
Cancers. Because of the prominent role of NLRC5 in orches-
trating the expression of MHC class I and class I-related genes, we
examined gene-expression profiles of biopsy samples from the co-
hort of 7,747 solid cancer patients in The Cancer Genome Atlas
(TCGA) database. The expression of HLA-B was highly correlated
with the level of NLRC5 expression in the entire cohort (rs = 0.753)
(Fig. 1A). Correlation analysis for gene expression among 14 cancer
types demonstrated that HLA-B and NLRC5 expression showed
high positive correlation (rs > 0.70) in nine cancer types and in-
termediate positive correlation (rs > 0.50) in five cancer types (Fig. 1
B and C), with the highest correlation observed in melanoma. In
addition toHLA-B, the expression ofHLA-A,HLA-C, B2M, LMP2,
LMP7 (PSMB8), and TAP1 was also highly correlated with NLRC5
expression in melanoma and other cancers (Fig. 1D and Fig. S1A).
Significance
Tumor antigen presentation to CD8+ T cells by MHC class I
molecules is crucial for immune responses against cancers,
whereas the loss of MHC class I is a common immune evasion
strategy used by cancers. However, the molecular mechanisms
leading to MHC class I deficiency have remained poorly de-
fined. We demonstrate here that MHC class I transactivator
(CITA)/NOD-like receptor (NLR) family, caspase recruitment
(CARD) domain containing 5 (NLRC5) is a major target for
cancer immune evasion. Reduced expression of MHC class I
and related genes in cancer is frequently associated with genetic
and epigenetic changes in NLRC5. The reduced NLRC5 expression
is linked to impaired CD8+ T-cell activation and poor patient
prognosis. These data indicate that CITA/NLRC5 is a novel prog-
nostic marker and potential therapeutic target of cancers.
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Because CITA/NLRC5-mediated MHC class I expression is crucial
for optimal activation and cytolytic activity of CD8+ T cells (18, 19),
we next examined the expression level of perforin (PRF1) or granzyme
A (GZMA), which are known to be associated with cytotoxic T-cell
activity in cancer tissues (23). Indeed, the cohort of 16 solid cancer
etiologies revealed a significant positive correlation between NLRC5
expression and PRF1 or GZMA (Fig. 1E and Fig. S1B). Although
PRF1 and GZMA are expressed in both activated CD8+ T cells and
natural killer (NK) cells, NLRC5 expression was correlated only with
CD8A but not with the NK cell marker CD56 (Fig. 1F and Fig. S1C).
These data indicate thatNLRC5 expression in cancer tissues is critical
for inducing CD8+ T-cell–dependent cytotoxic activity, likely through
the induction of MHC class I expression. Despite the critical function
of NLRC5 for MHC class I-dependent immune responses, there are
likely to be aberrant mechanisms which may reduce NLRC5 ex-
pression in cancers, as indicated by decreased NLRC5 expression in
multiple cancer types compared with normal tissues (Fig. 1G). Three
cancer types with higher expression of NLRC5 seemed to be
exceptions (Fig. S1D), perhaps because of a high inflammatory
state (hepatocellular carcinoma and colorectal carcinoma) (24,
25) or increased infiltration of hematopoietic cells character-
ized by high CD45 expression (brain tumors) (Fig. S1E).
Preferential Methylation of NLRC5 in Cancer Is Associated with
Impaired Cytotoxic T-Lymphocyte Activity. Epigenetic changes in
cancer cells represent an important mechanism to alter gene
expression in favor of cancer growth and immune evasion (26).
Abnormal methylation of CpG islands in promoter regions can
transcriptionally suppress genes that are unfavorable for cancer
growth (27). Treatment of various cancer cell lines with a DNA-
methylation inhibitor, 5-azacitidine (5-Aza), resulted in the up-
regulation of NLRC5 and HLA-B expression, suggesting that
methylation of the NLRC5 promoter might play a role in the loss
of MHC class I expression in cancer (Fig. 2A). Therefore, the
level of DNA methylation at a CpG island in the NLRC5 pro-
moter in various cancer types was quantified using a methylation-
specific probe (Fig. 2B). Methylation of the NLRC5 promoter
was observed at higher frequency in multiple cancers than in the
corresponding normal tissues (excluding prostate, thyroid, and
kidney, where high methylation was observed even in normal
tissues) (Fig. 2C and Fig. S2A). Furthermore, analysis of biopsy
samples from 6,523 solid cancer patients revealed that methyl-
ation of the NLRC5 promoter was negatively correlated with
NLRC5 expression (rs = −0.585) (Fig. 2D). Suppression of
NLRC5 expression by promoter methylation was observed in all
13 cancer types that we examined; an intermediate negative
correlation (rs = −0.50 to −0.70) was found in five cancer types,
and a low negative correlation (rs = −0.30 to −0.50) was found in
eight cancer types (Fig. S2 B and C). Moreover, the methylation
of the NLRC5 promoter was negatively correlated with the ex-
pression of HLA-B in all cancer types to various degrees (Fig. 2E
and Fig. S2C). NLRC5 promoter methylation also was negatively
correlated with the expression of HLA-A, HLA-C, B2M, LMP2,
LMP7, and TAP1 in melanoma and other cancers (Fig. 2E and
Fig. S2D). Reduced expression of MHC class I genes was spe-
cifically correlated with NLRC5 methylation because methyl-
ation of the promoter for CIITA, a master transcriptional
activator of MHC class II genes, did not correlate with the ex-
pression of HLA-B or other class I-related genes in the entire
cancer cohort or in melanoma (Fig. 2F and Fig. S2E). Strikingly,
NLRC5 methylation was negatively correlated with CD8A,
GZMA, and PRF1 but not with CD56 (Fig. 2 G and H and Fig.
S2 F and G). These data suggest that methylation of NLRC5 in
cancer cells results in the transcriptional suppression of NLRC5,
leading to reduced expression of MHC class I genes and evasion of
CD8+ cytotoxic T-cell–dependent antitumor activity. Because HLA
gene methylation also has been reported in cancer cells (10), the
methylation level of the NLRC5 promoter was compared with that
of other MHC class I and related genes. Although various degrees
of NLRC5 methylation were observed in all the different cancer
types examined (Fig. S2H), the DNA methylation was most severe
in NLRC5 among all class I-related genes tested in entire cancer
cohort (Fig. 2I). Moreover, methylation of the NLRC5 promoter
exhibited the most effective gene suppression among all class
I-related genes, because the negative correlation between DNA
methylation and gene expression was more prominent for NLRC5
than for other MHC class I-related genes (Fig. 2 D, J, and K and
Fig. S2I). Taken together, these data suggest that the methylation of
NLRC5, but not of other MHC class I genes, is used selectively in
various cancers as an immune evasion strategy for efficient sup-
pression of the MHC class I pathway.
Copy Number Loss of NLRC5 Is Associated with Reduced MHC Class I
Gene Expression. Changes in somatic gene copy number (CN) are
frequently observed in cancer cells and are associated with altered
gene-expression levels (28, 29). The analysis of CN in the cohort
of 7,730 cancer patients showed that all cancer types carry al-
terations in CN of the NLRC5 gene. CN loss (CN = 0 or 1) was
observed in 28.6% of all cancer patients, with the highest fre-
quency (72.2%) in ovarian cancer patients (Fig. 3A). Remarkably,
among MHC class I and related genes across the entire cancer
cohort and in ovarian cancer, the frequency of CN loss was
highest for NLRC5, followed by B2M (Fig. 3B and Fig. S3A),
again indicating that NLRC5 is a preferential target for cancer
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Fig. 1. Expressions of NLRC5 and MHC class I genes are positively correlated.
(A) Scatter plots for the expression of NLRC5 [x axis; log10 values in tran-
scripts per million (TPM)] and HLA-B (y axis; log10 values in TPM) in 16 tumor
types (n = 7,747). (B) Spearman rank correlation coefficients between the
expression of NLRC5 and HLA-B. Fourteen representative tumor types car-
rying at least 100 samples are shown. (C) Scatter plots for the expression of
NLRC5 and HLA-B in six tumor types showing high correlation coefficients.
(D) Scatter plots for the expression of NLRC5 and other MHC class I-related
genes in melanoma that have the highest correlation coefficients in B. (E)
Scatter plots for the expression of NLRC5 and GZMA or PRF1 in 16 tumor
types (n = 7,749). (F) Scatter plots for the expression of NLRC5 and CD8A in
16 tumor types (n = 6,277) or CD56 in 15 tumor types (n = 5,685). Pairwise
correlations in A–F were calculated using the Spearman’s ranked correlation
test; r, Spearman rho coefficient. (G, Left) NLRC5 expression in indicated
normal and tumor tissues. The bar inside the box corresponds to the median;
the box corresponds to the 25th–75th percentiles, and the error bars indicate
the confidence interval (fifth–95th percentile). Statistical significance was
determined by the Mann–Whitney test: **P < 0.01. (Right) The ratio of
NLRC5 expression level in tumor and normal tissues.
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immune evasion among genes involved in the MHC class I
pathway. Gene-expression analysis demonstrated that patients
with NLRC5 CN loss showed reduced expression levels of
NLRC5 and of MHC class I and related genes, including HLA-A,
HLA-B, HLA-C, B2M, LMP2, and LMP7 across the entire can-
cer cohort (Fig. S3B). The various degrees of reduction in
NLRC5 and class I gene expression were observed in samples of
numerous cancers that had CN loss, with the highest reduc-
tion rate found in breast cancer (Fig. S3 C and D). To distinguish
the effect of CN loss from that of NLRC5 methylation, can-
cer groups in which the NLRC5 promoter is not methylated
(β value <0.3) were analyzed for gene expression. Again, pa-
tients with NLRC5 CN loss exhibited decreased expression of
NLRC5 and MHC class I-related genes across the entire cancer
cohort and in breast cancer (Fig. 3C and Fig. S3E), indicating
that CN loss of NLRC5 results in the reduced expression of the
genes involved in the MHC class I pathway independently of
the methylation level of the NLRC5 promoter. Collectively,
these data indicate that cancer cells selectively lose NLRC5 at a
high frequency, resulting in reduced expression of MHC class I
and related genes.
Somatic Mutations in NLRC5 Are Correlated with Reduced Expression
of MHC Class I Genes. Because somatic mutations are another
important molecular mechanism of carcinogenesis (30), biopsy
samples from 16 solid cancer types were analyzed for somatic mu-
tations in NLRC5. A total of 142 patients were found to have
mutations, most of which (58.5%) were missense mutations (Fig. 4A).
Colon cancer patients exhibited the highest NLRC5 mutation
rate (8.6%), followed by melanoma (6.8%) (Fig. 4B). Similar to
promoter methylation and CN loss, somatic mutations were most
frequently observed in NLRC5 among all MHC class I and re-
lated genes (Fig. 4C). Mutations were distributed across the
entire NLRC5 coding region with no obvious hot spots (Fig. S4).
To determine whether those mutations affect NLRC5 function,
mutations (n = 13) observed in more than one patient were
analyzed for their ability to induce MHC class I gene expression
via a reporter gene assay that employs the HLA-B promoter and
various NLRC5 expression vectors generated by site-directed
mutagenesis (Fig. 4D). As shown in Fig. 4E, 7 of the 13 NLRC5
mutants exhibited complete loss of induction for HLA-B pro-
moter activity, although it is possible that NLRC5 mutants that
appeared to be functional in this reporter assay may carry al-
tered function at more physiological settings. The data dem-
onstrate that the majority of NLRC5 mutations in cancer
patients are true loss-of-function mutations. Indeed, correlation
analysis of HLA-B and NLRC5 expression confirmed the ten-
dency for reduced HLA-B expression levels in patients with
NLRC5 mutations compared with patients with wild-type NLRC5
(Fig. 4F). To substantiate this observation further with statistical
analysis, we plotted the ratio of MHC class I genes to NLRC5 to
reflect gene induction by NLRC5. As expected, the ratio of MHC
class I to NLRC5 expression was decreased in the NLRC5 mutant
group (Fig. 4G). These data indicate that in multiple cancers
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Fig. 2. Preferential DNA methylation in the NLRC5 promoter in cancer cells is associated with impaired MHC class I-dependent cytotoxic T-cell activity.
(A) Indicated cancer cell lines were treated with 3 μM of 5-Aza for the indicated time periods, and NLRC5 and HLA-B expression was quantified by quantitative
PCR. Data are representative of three independent experiments and are shown as means ± SD. Statistical significance was determined by the paired t test:
**P < 0.01. (B) Schematic representation of the methylation-specific probe on the NLRC5 promoter region. The NLRC5 promoter has a CpG island of ∼578 bp
starting at position −278. To examine the methylation status of the NLRC5 promoter, a methylation-specific probe (cg16411857, blue line) on the CpG island
was used. The transcription start site is indicated as −1; the STAT1-binding site GAS is at −570. (C, Upper) The methylation rate of the NLRC5 promoter in 10
indicated cancer types and normal tissues. (Lower) The difference in the NLRC5 promoter methylation rate in tumor and normal tissues. A β value over 0.3 was
considered as methylated. Statistical significance was determined by the χ2 test: *P < 0.05; **P < 0.01. (D) Scatter plots showing the expression of NLRC5
(y axis; log10 values in TPM) and the methylation level of the NLRC5 promoter (x axis; β values) in 15 tumor types (n = 6,523). (E) Scatter plots for the ex-
pression of various MHC class I-related genes and the methylation level of the NLRC5 promoter in melanoma (n = 468). (F) Scatter plots for HLA-B expression
and methylation level of CIITA promoter in 15 tumor types (n = 5,667). (G) Scatter plots for the expression of GZMA or PRF1 and the methylation level of the
NLRC5 promoter in 15 tumor types (n = 6,528). (H) Scatter plots for CD8A expression in 15 tumor types (n = 6,277) or CD56 expression and methylation level of
the NLRC5 promoter in 14 tumor types (n = 5,685). (I) Dot plots for the methylation level of various MHC class I-related genes (x axis; β values) in all cancer
types (16 tumor types, n = 6,557). The median values are indicated by vertical bars. Statistical significance was determined by the Mann–Whitney test: **P <
0.01. (J) Spearman rank correlation coefficient between the expression and methylation of indicated MHC class I-related genes in 15 tumor types (n = 6,419).
(K) Scatter plots for the expression and methylation level of various MHC class I-related genes in 15 tumor types (n = 6,419). In D–H, J, and K pairwise
correlations were calculated using the Spearman’s ranked correlation test. r, Spearman rho coefficient.
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somatic mutations occur preferentially in NLRC5 as compared
with other MHC class I-related genes and are associated with
the reduced expression of genes involved inMHC class I-mediated
antigen presentation.
The Expression of NLRC5 Is Correlated with Survival of Cancer
Patients. Because MHC class I expression and cytotoxic CD8+
T-cell infiltration in tumors are critical for immunological defense in
cancer patients, we analyzed the effect of NLRC5 on overall sur-
vival. Cancer patients were stratified into quartiles based onNLRC5
expression. The analysis of 5-year survival of patients with 16 dif-
ferent cancer types revealed that the quartile with highest NLRC5
expression showed significantly better survival than the quartile
with lowest NLRC5 expression in six cancer types (melanoma,
rectal cancer, bladder cancer, uterine cancer, cervical cancer,
and head/neck cancer) (Fig. 5A and Fig. S5A). Kaplan–Meier
survival analysis also demonstrated that the high NLRC5 ex-
pression was associated with significantly improved cumula-
tive survival in melanoma, bladder cancer, and cervical cancer
(Fig. 5B). The most striking differences were seen in melanoma
and bladder cancer, with 5-year survival rates of 36% and 34%,
respectively, in the NLRC5-low group compared with 71% and
62%, respectively, in the NLRC5-high group. In addition toNLRC5,
the expression of NLRC5-dependent (HLA-A, -B, -C, B2M,
LMP2, LMP7, and TAP1) (Fig. 5C) but not NLRC5-independent
(Calreticulin, Tapasin, ERp57, and ERAP1) (Fig. 5D) genes in-
volved in MHC class I antigen presentation was positively asso-
ciated with cumulative survival of melanoma patients. The expression
of markers for cytotoxic CD8+ T-cell activity (CD8A, GZMA, and
PRF1) (Fig. 5E) but not of NK cells (CD56) (Fig. S5B) also was
correlated with better cancer patient survival, most likely through
NLRC5-dependent MHC class I antigen presentation. Interestingly,
high methylation of NLRC5 but not of other MHC class I and re-
lated genes (HLA-A, -B, -C, B2M, LMP2, LMP7, and TAP1)
was associated with poor survival in melanoma and bladder
cancer, indicating that aberrant epigenetic changes specifically
in NLRC5 in cancer cells impacted clinical outcomes (Fig. 5F
and Fig. S5 C and D). Intriguingly, brain cancer (glioma/
glioblastoma) showed an opposite correlation, with a signifi-
cantly lower 5-year survival rate in the cohort with high
NLRC5 expression (Fig. S5A). Although the exact mechanism
is uncertain, this effect might be caused by the unique anatomy
of brain. Because brain mass is limited by the skull, unlike other
cancers, one major life-threatening complications of brain tu-
mors is the development of brain edema, which is associated with
inflammatory events including impaired blood–brain barrier and
destruction of normal brain tissues (31, 32). In fact, patients with
brain tumors are commonly treated with anti-inflammatory drugs
such as corticosteroids (32, 33). Taken together, these findings
show that NLRC5 expression is correlated with higher survival in
multiple cancer types, with the exception of brain cancer, in
which it appears to be a negative prognostic factor. Strikingly,
DNA methylation of NLRC5 alone, but not of other MHC class
I-related genes, is linked to poor patient survival in melanoma
and bladder cancer, further signifying the role of NLRC5 in
tumor immunity.
Discussion
This study demonstrates that CITA/NLRC5 is a major target for
facilitating immune evasion by cancer cells (Fig. 6). During onco-
genic transformation and cancer evolution, tumor cells need to
develop ways to escape from the host immune system to sustain de-
velopment, growth, invasion, and metastasis. Reduction, alteration,
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box plots show NLRC5 and MHC class I-related gene expression in the NLRC5
diploid group or in the CN-loss group in breast cancer. The bar inside the box
corresponds to the median, the box corresponds to the 25th–75th percentile,
and the error bars indicate the confidence interval (fifth–95th percentile).
Statistical significance was determined by the Mann–Whitney test: **P < 0.01.
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Fig. 4. Somatic mutations in NLRC5 are correlated with reduced expression
of MHC class I genes. (A) Pie chart representing the percentage distribution
of different types of mutations in NLRC5 in various cancer patients (n =
7,752). (B) Mutation rate in NLRC5 for 16 tumor types (n = 9,061). (C) Mu-
tation rate in the indicated genes for 16 tumor types. Statistical significance
was determined by the χ2 test (n = 9,061): **P < 0.001. (D) Representation of
NLRC5 indicating 13 mutations found in at least two different cancer patients.
(E) HEK293T cells were cotransfected with either empty control vector or the
respective NLRC5 mutant plasmid with HLA-B reporter plasmid, and HLA-B
promoter activity was assessed by the dual-luciferase assay and normalized
against Renilla firefly activity. Data are representative of two independent ex-
periments performed in duplicate and are plotted as fold induction with respect
to the control vector. The error bars indicate SD. (F) Scatter plots for the ex-
pression of NLRC5 and HLA-B for the NLRC5wild-type group (blue circle) and the
NLRC5mutant group (black cross) in 16 tumor types (n = 7,752). (G) Box plots for
the expression level of MHC class I-related genes normalized by the expression
level of NLRC5 in 16 tumor types that are either NLRC5 wild type or NLRC5
mutant. The bar inside the box corresponds to the median; the box corresponds
to the 25th–75th percentile, and the error bars indicate the confidence interval
(fifth–95th percentile). Statistical significance was determined by the Mann–
Whitney test: *P < 0.05; **P < 0.01.
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or total loss of tumor antigen expression is critical to avoid
killing via activation of cytotoxic CD8+ T cells and can be
achieved by at least three mechanisms: (i) lack of expression of
tumor antigen; (ii) loss of MHC class I molecules; (iii) im-
paired function or expression of genes in the class I antigen-
presentation pathway such as in the immunoproteasome or
class I peptide loading complex in the endoplasmic reticulum
(1). Impaired function or expression of CITA/NLRC5, a master
regulator of MHC class I genes, affects the latter two steps
concurrently (11, 12), thus making NLRC5 an attractive target
for cancer cells to evade CD8+ T-cell–dependent immune re-
sponses. Indeed, the expression of NLRC5 is correlated with
markers for cytotoxic CD8+ T-cell activity and is associated
with better prognosis with prolonged patient survival in multi-
ple cancers (Figs. 1 E and F and 5 A and B). Furthermore, the
expression of NLRC5-dependent genes (but not the expression
of independent genes) involved in MHC class I antigen pre-
sentation is associated with cancer patient survival, further
supporting the significance of the NLRC5-dependent MHC
class I transactivation pathway in antitumor immunity (Fig. 5 C
and D). Several lines of evidence demonstrated that cancer
cells have evolved to target NLRC5 preferentially for immune
evasion. First, the NLRC5 promoter is more highly methylated
than any other gene in the MHC class I pathway (Fig. 2I).
Second, the methylation-mediated suppression of gene ex-
pression is most effective for NLRC5 (Fig. 2 D, J, and K and
Fig. S2I). Third, among all MHC class I-related genes, CN loss
is most frequently observed in NLRC5 (Fig. 3B and Fig. S3A).
Fourth, somatic mutations were observed more frequently in
NLRC5 than in other MHC class I-related genes (Fig. 4C).
Strikingly, the methylation status of NLRC5, but not of other
MHC class I and related genes, was associated with changes in
patient survival of melanoma and bladder cancer (Fig. 5F and
Fig. S5 C and D). These data identify NLRC5 as a major target
of immune evasion in cancers. Although NLRC5 is expressed
in both cancer and infiltrating T cells, it is unlikely that aber-
rant promoter methylation, CN loss, and mutations in NLRC5
occur in normal infiltrating cells. Therefore, these data
strongly indicate that genetic as well as epigenetic alterations
within the cancer cells impact MHC class I-dependent im-
mune responses through altered activity of NLRC5. Although
this study focused on the transcriptional regulation of
NLRC5, it is possible that NLRC5 may be regulated at the
posttranscriptional level, including translational, protein sta-
bility, and cellular localization alterations in cancer cells; this
possibility needs to be addressed in a future study. Alternative
mechanisms by which NLRC5 affects cancer progression
could be via regulation of cytokines such as type I IFNs, IL-6,
or TNF-α because NLRC5 was reported to be a regulator of
TLR response, type I IFN production, and inflammasome acti-
vation in early studies. However, it is unclear if these proposed
innate immune functions of NLRC5 exist in cancer cells, because
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A
Fig. 5. The expression of NLRC5 is correlated with
better survival in multiple cancer types. Patients were
divided into four groups by the level of indicated gene
expression or methylation, and the top (high) and the
bottom (low) quartiles were analyzed. (A, Left) Five-
year survival rate in high and low NLRC5 expression
groups for indicated tumor types. (Right) Difference in
the 5-year survival rate in groups with high and low
NLRC5 expression. Statistical significance was deter-
mined by the χ2 test: *P < 0.05; **P < 0.01. (B) Kaplan–
Meier survival curves for indicated tumor types in
groups with low and high NLRC5 expression.
(C) Kaplan–Meier survival curves for melanoma pa-
tients with low and high expression of the indicated
NLRC5-dependent MHC class I-related genes. (D)
Kaplan–Meier survival curves for melanoma patients
with low and high expression of the indicated NLRC5-
independent MHC class I-related genes. (E) Kaplan–
Meier survival curves for melanoma patients with low
and high expression of CD8A and the indicated
markers for cytotoxic CD8+ T-cell activity. (F) Kaplan–
Meier survival curves for melanoma patients with low
and high methylation of theNLRC5 promoter and the
indicated MHC class I-related genes. In B–F statistical
significance was determined by the log-rank test and
the Gehan–Breslow–Wilcoxon test.
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Fig. 6. Model of cancer evolution targeting NLRC5 for immune evasion.
NLRC5-dependent MHC class I expression is crucial for CD8+ T-cell–mediated
antitumor responses and the elimination of cancer cells. Genetic and epi-
genetic changes, such as mutation, CN loss, or promoter methylation of
NLRC5 occur during the evolution of cancer cells, leading to an impaired
MHC class I system. These changes result in an impaired ability to elicit an-
titumor CD8+ T-cell responses and reduced infiltration in cancer tissues.
Cancer cells successful in immune evasion cause efficient tumor develop-
ment, leading to poor prognosis of cancer-bearing patients. Cancer cells
(gray) and CD8+ T cells (orange) are shown.
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the data were not reproducible among different laboratories and
by in vivo experiments using Nlrc5-deficient mice (12).
Because high expression and low methylation of NLRC5 are
correlated with better survival of cancer patients, these data
suggest that NLRC5 expression and methylation status are
useful biomarkers for patient prognosis and survival in multi-
ple cancers. Furthermore, these data indicate that NLRC5 is
an attractive therapeutic target in cancer patients. Checkpoint
blockade immunotherapy such as anti-CTLA4 or anti–PD-1/
PD-L1 therapy has emerged as a leading cancer treatment
(34), although its efficacy is hampered when cancer cells suc-
cessfully evade immune responses. Therapeutics augmenting
NLRC5 activity could compensate for this deficit by breaking
cancer immune evasion in a broad range of tumor types. In-
terestingly, it has been reported that currently used therapies,
such as an EGF receptor inhibitor (cetuximab) or a B-Raf
inhibitor (vemurafenib), enhance MHC class I expression via
IFN-γ (35, 36). Therefore, these currently available therapies,
originally designed to disrupt oncogenic signaling, may me-
diate their effects in part via the NLRC5-dependent MHC
class I pathway.
Methods
For a more detailed discussion of the materials and methods, see SI Methods.
Tumor types were selected based on the availability of gene-level RNA-
sequencing (RNA-seq) expression data from TCGA. RNA-seq data in normal
tissues were from the GTEx web portal. The TCGA abbreviations for the
samples used in this study are given in Table S1. The numbers of samples of
each tumor type are detailed in Table S2. The primers used for the construc-
tion of selected NLRC5 mutant expression vectors are listed in Table S3.
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